Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
about
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenBisphosphonates: mechanism of action and role in clinical practiceOsteoporosis and its managementIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisUpdate on bazedoxifene: a novel selective estrogen receptor modulatorCancer treatment-related bone disease.Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.No association between the aluminium content of trabecular bone and bone density, mass or size of the proximal femur in elderly men and womenUK clinical guideline for the prevention and treatment of osteoporosisAdoption of once-monthly oral bisphosphonates and the impact on adherence.Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial.Safety of drugs used in the treatment of osteoporosis.Once-monthly risedronate for postmenopausal osteoporosisHigher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged ratsAdherence and occurrence of fractures after switching to once-monthly oral bisphophonatesBack pain in patients with severe osteoporosis on teriparatide or antiresorptives: a prospective observational study in a multiethnic population.Updated recommendations for the diagnosis and management of osteoporosis: a local perspectiveIf you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosisRecommendations for evaluation and management of bone disease in HIV.Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonatesEfficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review.Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.Long-term experience with alendronate in the treatment of osteoporosis.How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.Clinical application of biochemical markers of bone turnover.Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation.Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.Management of osteoporosis among home health and long-term care patients with a prior fractureComparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.Is bone quality associated with collagen age?Prevention of osteoporosis-related fractures among postmenopausal women and older men.Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates.Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
P2860
Q24612411-C582216C-AD9E-4B35-B977-771DB25FF004Q24644708-639515C6-FDCA-4563-97EA-E6F71350AF24Q24670075-46B33325-3D08-4FC7-8084-F899B0726F51Q24680238-54AEB024-7634-41FA-9D3A-CBAABA225DB0Q28258998-C7268A16-5DFE-4EAC-A981-24701688B31BQ30438185-FC2A18B9-CFC4-4AF0-95AD-7C7798B23156Q31165701-5A8D6F37-D11E-4331-AF0F-FCE27B5A3D4EQ33254998-EE50DC82-9E2A-4BB7-80A3-741551413851Q33581078-98DA9750-8E2C-4B05-ACA1-FEEEBF15605BQ33701964-9DC21A81-7EB2-4D56-B7A9-32363643FFC2Q33746674-30080C88-0DD7-4F0C-BDEF-D29C999AAE48Q33949479-66CFBFCC-50B5-4FB6-8C43-DE751E2B85BAQ34272000-9314D881-A46C-4B9F-8248-1538FCE4770BQ34411999-9F4A7E36-C7A7-453A-8D0D-18EC56F42181Q34821660-5469486B-0720-4674-BB7F-11BCF04EAA63Q34952374-A1659C25-08DC-4E68-8E39-7988AA2200E5Q35008617-C15D62DF-B860-481D-BD8C-06B978A805C5Q35050249-4579244C-A2DC-4CB5-A4D9-9E4282B8A5EDQ35053491-DB17909B-0CDF-4307-A32F-8D6D8EEF6A4CQ35451868-9D681111-A37B-4FC3-9944-F4B228DC4099Q35505244-66F7BDFB-3642-4C69-9C04-0B2321087EFBQ35533455-432EA0A9-5549-4DCD-88A2-CAAA4BA816D7Q35637164-61E72DA9-58BC-495C-91F5-3DC93D2D0AEFQ35954529-46533AD0-1797-44DB-975B-9A16BF6E1A2CQ36056975-BD5CFFA2-448C-43AD-86A1-7F1C21C2991CQ36459422-9AB7CAA0-4F98-4FC3-9979-880F41ED82BAQ36491814-F7B81E07-2A72-42AA-8FD2-9E02C8537158Q36492900-CF70402C-3FC5-477A-A4D9-3E6887CA0E93Q36658915-B08E3570-0CA6-4226-B396-A76FEA0C7681Q36897425-D3997457-69EE-4F78-B049-8BAE068A3830Q36922156-8E4372CB-3EA8-4D80-AC3E-2FD5DE38BE50Q36979311-A0D49360-9068-44C4-ADE2-5AA58FC5B3D5Q37037296-EE8CD71C-3871-4F63-935D-28F4AB59A38AQ37250572-6C964392-4405-4C4A-A3B4-83FBA49E56DEQ37287270-5AC487B9-95D4-49AF-B224-F81B159B9D4DQ37402282-8634A102-5D2B-4344-B5E0-FA293B5F2529Q37426367-3B1606C0-43D7-419E-A26A-5D7F28FA654AQ37428448-7370A797-689B-446D-96C1-7F7E58B3B803Q37725841-079784FA-E920-49FC-8026-015E113EC2CFQ37768696-64227D38-A32C-4A5A-9E0B-51B88DDBF73B
P2860
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Daily and intermittent oral ib ...... : results from the BONE study.
@en
Daily and intermittent oral ib ...... : results from the BONE study.
@nl
type
label
Daily and intermittent oral ib ...... : results from the BONE study.
@en
Daily and intermittent oral ib ...... : results from the BONE study.
@nl
prefLabel
Daily and intermittent oral ib ...... : results from the BONE study.
@en
Daily and intermittent oral ib ...... : results from the BONE study.
@nl
P2093
P1476
Daily and intermittent oral ib ...... : results from the BONE study.
@en
P2093
C Christiansen
C H Chesnut
J A Stakkestad
J Gilbride
P D Delmas
R C Schimmer
R R Recker
P2888
P304
P356
10.1007/S00198-004-1602-9
P407
P577
2004-04-08T00:00:00Z